This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
by Zacks Equity Research
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
by Zacks Equity Research
Autonomix secures key U.S. patent for its groundbreaking catheter-based nerve-sensing and stimulation tech, aiming to transform treatment across major diseases
Here's Why Investors Should Consider Retaining Danaher Stock Now
by Zacks Equity Research
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
Wall Street Bulls Look Optimistic About CVS Health (CVS): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), CVS Health (CVS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
by Zacks Equity Research
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
Is Trending Stock CVS Health Corporation (CVS) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
by Zacks Equity Research
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
by Zacks Equity Research
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
by Zacks Equity Research
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
by Zacks Equity Research
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now
by Zacks Equity Research
Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
GEHC Stock May Rise Following the Launch of AI-Based CleaRecon DL
by Zacks Equity Research
GE HealthCare launches CleaRecon DL, an AI-powered 3D imaging tech that enhances cone-beam CT scans by reducing artifacts, improving clarity for better interventional care.
Here's Why CVS Health (CVS) Looks Ripe for Bottom Fishing
by Zacks Equity Research
CVS Health (CVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Here's Why You Should Add DexCom Stock to Your Portfolio Now
by Zacks Equity Research
DXCM continues to raise investor optimism due to its strong product portfolio.
Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up
by Zacks Equity Research
DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.
GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use
by Zacks Equity Research
GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart diagnostics for children with safer imaging.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
5 Low Price-to-Book Value Stocks to Buy in May
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.
Top Analyst Reports for Oracle, IBM & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), IBM Corp. (IBM) and Merck & Co., Inc. (MRK), as well as a micro-cap stock Earth Science Tech, Inc. (ETST).
CVS Health Stock Rallies 38% in May: Is it a Buy Amid PBM Pressure?
by Urmimala Biswas
CVS' pharmacy segment continues to lead the industry, processing over 1.7 billion prescriptions annually while delivering high medication adherence.
Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer
by Zacks Equity Research
StoneCo, Centene, CVS Health and Pfizer have been highlighted in this Screen of The Week article.
DaVita Stock Down Despite Q1 Earnings Beat, Margins Contract
by Zacks Equity Research
Strength in revenue per treatment and dialysis patient service revenues drives DVA's first-quarter 2025 performance despite a year-over-year decline in normalized non-acquired treatment.
4 Value Picks to Ride the Market Rebound After US-China Trade Thaw
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. STNE, CNC, CVS & PFE boast a low P/CF ratio.